Neutrophil-mediated Clinical Nanodrug for Treatment of Residual Tumor After Focused Ultrasound Ablation

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2021 Oct 30

PMID 34715854

Citations 5

Authors

Jian Shen

Junnian Hao

Yini Chen

Hairong Liu

Jianrong Wu

Bing Hu

Yan Wang

Yuanyi Zheng

Xiaojun Cai

Affiliations

Soon will be listed here.

Abstract

Background: The risk of local recurrence after high-intensity focused ultrasound (HIFU) is relatively high, resulting in poor prognosis of malignant tumors. The combination of HIFU with traditional chemotherapy continues to have an unsatisfactory outcome because of off-site drug uptake.

Results: Herein, we propose a strategy of inflammation-tendency neutrophil-mediated clinical nanodrug targeted therapy for residual tumors after HIFU ablation. We selected neutrophils as carriers and PEGylated liposome doxorubicin (PLD) as a model chemotherapeutic nanodrug to form an innovative cell therapy drug (PLD@NEs). The produced PLD@NEs had a loading capacity of approximately 5 µg of PLD per 10 cells and maintained the natural characteristics of neutrophils. The targeting performance and therapeutic potential of PLD@NEs were evaluated using Hepa1-6 cells and a corresponding tumor-bearing mouse model. After HIFU ablation, PLD@NEs were recruited to the tumor site by inflammation (most in 4 h) and released PLD with inflammatory stimuli, leading to targeted and localized postoperative chemotherapy.

Conclusions: This effective integrated method fully leverages the advantages of HIFU, chemotherapy and neutrophils to attract more focus on the practice of improving existing clinical therapies.

Citing Articles

Harnessing myeloid cells in cancer.

Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D Mol Cancer. 2025; 24(1):69.

PMID: 40050933 PMC: 11887392. DOI: 10.1186/s12943-025-02249-2.

High-intensity focused ultrasound ablation to increase tumor-specific lymphocytes in prostate cancer.

Su S, Wang Y, Lo E, Tamukong P, Kim H Transl Oncol. 2025; 53:102293.

PMID: 39862483 PMC: 11803900. DOI: 10.1016/j.tranon.2025.102293.

Different origin-derived exosomes and their clinical advantages in cancer therapy.

Jin X, Zhang J, Zhang Y, He J, Wang M, Hei Y Front Immunol. 2024; 15:1401852.

PMID: 38994350 PMC: 11236555. DOI: 10.3389/fimmu.2024.1401852.

Application of high intensity focused ultrasound combined with nanomaterials in anti-tumor therapy.

Zhang X, He N, Zhang L, Dai T, Sun Z, Shi Y Drug Deliv. 2024; 31(1):2342844.

PMID: 38659328 PMC: 11047217. DOI: 10.1080/10717544.2024.2342844.

Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy.

Xie X, Zhang J, Wang Y, Shi W, Tang R, Tang Q Mater Today Bio. 2024; 24:100926.

PMID: 38179429 PMC: 10765306. DOI: 10.1016/j.mtbio.2023.100926.

References

Lang B, Woo Y, Wong C . High-Intensity Focused Ultrasound for Treatment of Symptomatic Benign Thyroid Nodules: A Prospective Study. Radiology. 2017; 284(3):897-906. DOI: 10.1148/radiol.2017161640. View

Chu D, Dong X, Shi X, Zhang C, Wang Z . Neutrophil-Based Drug Delivery Systems. Adv Mater. 2018; 30(22):e1706245. PMC: 6161715. DOI: 10.1002/adma.201706245. View

Raemdonck K, Braeckmans K, Demeester J, De Smedt S . Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery. Chem Soc Rev. 2013; 43(1):444-72. DOI: 10.1039/c3cs60299k. View

Jeon N, Baskaran H, Dertinger S, Whitesides G, Van De Water L, Toner M . Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. Nat Biotechnol. 2002; 20(8):826-30. DOI: 10.1038/nbt712. View

Cui Y, Zhang H, Meadors J, Poon R, Guimond M, Mackall C . Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood. 2009; 114(18):3831-40. PMC: 2773493. DOI: 10.1182/blood-2009-03-212134. View

Kalogeridi M, Zygogianni A, Kyrgias G, Kouvaris J, Chatziioannou S, Kelekis N . Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review. World J Hepatol. 2015; 7(1):101-12. PMC: 4295187. DOI: 10.4254/wjh.v7.i1.101. View

Al-Bataineh O, Jenne J, Huber P . Clinical and future applications of high intensity focused ultrasound in cancer. Cancer Treat Rev. 2011; 38(5):346-53. DOI: 10.1016/j.ctrv.2011.08.004. View

Chu K, Dupuy D . Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014; 14(3):199-208. DOI: 10.1038/nrc3672. View

OBrien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A . Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15(3):440-9. DOI: 10.1093/annonc/mdh097. View

10.

Zhang L, Zhang Y, Xue Y, Wu Y, Wang Q, Xue L . Transforming Weakness into Strength: Photothermal-Therapy-Induced Inflammation Enhanced Cytopharmaceutical Chemotherapy as a Combination Anticancer Treatment. Adv Mater. 2018; 31(5):e1805936. DOI: 10.1002/adma.201805936. View

11.

Chen E, Chen B, Su Y, Chang Y, Cheng T, Barenholz Y . Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin Formation of the Membrane Attack Complex. ACS Nano. 2020; 14(7):7808-7822. DOI: 10.1021/acsnano.9b07218. View

12.

Chu D, Dong X, Zhao Q, Gu J, Wang Z . Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration. Adv Mater. 2017; 29(27). PMC: 5510494. DOI: 10.1002/adma.201701021. View

13.

Urban C, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W . Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 2009; 5(10):e1000639. PMC: 2763347. DOI: 10.1371/journal.ppat.1000639. View

14.

Langhans S . Three-Dimensional Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol. 2018; 9:6. PMC: 5787088. DOI: 10.3389/fphar.2018.00006. View

15.

Bae Y, Park K . Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153(3):198-205. PMC: 3272876. DOI: 10.1016/j.jconrel.2011.06.001. View

16.

Geering B, Gurzeler U, Federzoni E, Kaufmann T, Simon H . A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils. Blood. 2011; 117(22):5953-62. DOI: 10.1182/blood-2010-11-322206. View

17.

Chen X, Novak P, Benson Jr D, Webber J, Hennings L, Shafirstein G . An alternating focused ultrasound system for thermal therapy studies in small animals. Med Phys. 2011; 38(4):1877-87. PMC: 3069994. DOI: 10.1118/1.3553405. View

18.

Gabizon A, Martin F . Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997; 54 Suppl 4:15-21. DOI: 10.2165/00003495-199700544-00005. View

19.

Choi Y, Han H, Jeon S, Yoon H, Kim H, Kwon I . Deep Tumor Penetration of Doxorubicin-Loaded Glycol Chitosan Nanoparticles Using High-Intensity Focused Ultrasound. Pharmaceutics. 2020; 12(10). PMC: 7650702. DOI: 10.3390/pharmaceutics12100974. View

20.

Klingler H, Susani M, Seip R, Mauermann J, Sanghvi N, Marberger M . A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound. Eur Urol. 2007; 53(4):810-6. DOI: 10.1016/j.eururo.2007.11.020. View